HLA-C and graft versus host disease: To mitigate the risk of GvHD and enhance persistence, allogeneic T-cells can be genetically modified using CRISPR/Cas9-based editing, for example, by knocking out the TCR to eliminate GvHD potential, and MHC molecules to reduce host-mediated rejection.